Genesis Care Pty Limited is in Chapter 11 with the supported record pointing to a lender-funded restructuring track built around stabilization, DIP liquidity, and a potential sale or restructuring of the U.S. business. The debtors filed on June 1, 2023, in the Southern District of Texas, with multiple affiliated operating entities commencing cases the same day through their Chapter 11 voluntary petitionsDkt. 1. CEO David Young tied the filing to liquidity pressure and operating deterioration, particularly in the U.S. platform acquired through 21st Century Oncology, citing declining revenue, operational inefficiencies, outdated equipment, increased competition, COVID-related volume disruption, labor pressure, and the refusal of prepetition lenders in April 2023 to fund roughly AUD $76 million under revolving facilities in the Young first-day declarationDkt. 19.
The capital structure entering the cases was dominated by approximately $1.7 billion of funded debt, including about $1.547 billion of Term Loan B obligations, $81 million of revolving credit exposure, and $87 million of shareholder loans from KKR- and Asia Pacific Healthcare-linked parties, as described in the Young first-day declarationDkt. 19. To keep the oncology network operating through Chapter 11, the debtors lined up an $800 million DIP facility with an ad hoc term lender group, including $200 million of new-money liquidity, and paired that financing with milestones requiring rapid interim and final DIP relief, plan filing, and confirmation deadlines.
The case posture reflected in the provided record is therefore not a free-fall liquidation but a financed Chapter 11 designed to preserve going-concern value while testing a restructuring or sale path for the U.S. operations. No later plan, sale-order, confirmation, effective-date, or upcoming-hearing materials are included in the context pack, so the near-term milestones supported here remain the first-day DIP and plan milestones described at filing rather than a later case outcome.